Robert Aleksandrowicz, CEO of Cellis, will represent the company at two Johnson & Johnson Innovation events exploring the latest advances in intratumoral oncology:
Inside Out: Breakthroughs in Intratumoral Approaches
🗓 October 18, 2025 | 20:45–21:30 CEST
📍 Spreespeicher Grande Room, Berlin
🌐 https://intoberlin.splashthat.com/
Beyond the Needle: Building the Future of Intratumoral Oncology
🗓 October 23, 2025 | 17:25–18:00 CEST
📍 MC3 Main Campus Convention Center, Allschwil (Basel)
🌐 https://intobasel.splashthat.com/
Organized by Johnson & Johnson’s Interventional Oncology (INTO), these events convene international experts to discuss how targeted, locally delivered therapies—oncolytic, immune-modulating, or cell-based—can be integrated with systemic treatments to improve precision, efficacy, and patient outcomes.
The Berlin panel “Inside Out” will focus on the science and clinical rationale behind intratumoral delivery, while the Basel discussion “Beyond the Needle” will highlight emerging technologies and collaborative strategies shaping the field.
Building on insights from his presentation at the JLABS CEO Summit 2025, Robert Aleksandrowicz will outline how Cellis’ macrophage-based cell therapy platform can advance the next generation of intratumoral and immune-driven cancer treatments.
